All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Abstract

Preparation of PEGylated Liposomal Ginsenoside;Formulation Design and in vitro Evaluation

Author(s): Y. Q. CUI, P. YANG1, P. SUN1, Y.D.YAN1, G.Y.JIN1* AND J.S.QUAN
Department of pharmaceutics, College of pharmacy, Yanbian University, 1Antu County Health Supervision Institute, 2Department of pharmacy, Yanbian University Hospital, Jilin, 133000, 3Beijing Fogangren Bio-Pharma Limited, Beijing, 102628, 4Department of Radiology, Yanbian University Hospital, Jilin, 133000, China

Correspondence Address:
Department of pharmaceutics, College of pharmacy, Yanbian University, China, E-mail: [email protected]


In this study, ginsenoside Rg3-loaded PEGylated liposomes were prepared and optimized using the Box- Behnken design. These liposomes were characterized, the cumulative release profiles were investigated and compared with ginsenoside Rg3-loaded liposomes in vitro. To improve the stability ginsenoside Rg3-loaded PEGylated liposomes were freeze-dried and the lyoprotectants to be added were screened. The results showed that the liposomes have a small particle size (152.58±0.74 nm) and spherical shape. The encapsulation efficiency and drug-loading rate were approximately 85.24±1.02 and 7.44±0.08 %, respectively. For lyoprotectants, 2 % lactose was chosen as the lyophilized protectant according to the appearance, re-dispersity, particle size, and entrapment efficiency of lyophilization of ginsenoside Rg3- loaded PEGylated liposomes. In vitro release showed that ginsenoside Rg3-loaded PEGylated liposomes showed a more obvious sustained release effect, which suggests that ginsenoside Rg3-loaded PEGylated liposomes might enhance the therapeutic effect of ginsenoside Rg3.

Full-Text | PDF